CoChat

In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris

Open access
Hager, Christopher L., Larkin, Emily L., Long, Lisa, Zohra Abidi, Fatima, Shaw, Karen J., Ghannoum, Mahmoud A. · 2018 · Antimicrobial Agents and Chemotherapy

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Candida auris is an emerging multidrug-resistant yeast that has been responsible for invasive infections associated with high morbidity and mortality. C. auris strains often demonstrate high fluconazole and amphotericin B MIC values, and some strains are resistant to all three major antifungal classes. We evaluated the susceptibility of 16 C. auris clinical strains, isolated from a wide geographical area, to 10 antifungal agents, including APX001A, a novel agent that inhibits the fungal protein Gwt1 (glycosylphosphatidylinositol-anchored wall transfer protein 1). APX001A demonstrated significantly lower MIC 50 and MIC 90 values (0.004 and 0.031 μg/ml, respectively) than all other agents tested. The efficacy of the prodrug APX001 was evaluated in an immunocompromised murine model of disseminated C. auris infection. Significant efficacy (80 to 100% survival) was observed in all three APX001 treatment groups versus 50% survival for the anidulafungin treatment group. In addition, APX001 showed a significant log reduction in CFU counts in kidney, lung, and brain tissue (1.03 to 1.83) versus the vehicle control. Anidulafungin also showed a significant log reduction in CFU in the kidneys and lungs (1.5 and 1.62, respectively) but did not impact brain CFU. These data support further clinical evaluation of this new antifungal agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.02319-17

Cites

Statistics

Figures

FIG 1 Survival curves in mice infected with C. auris CBS 12766. Treatments were administered by i.p. injection (n = 10/group): APX001 at doses of 78 mg/kg BID, 78 mg/kg TID, or 104 mg/kg BID; 10 mg/kg anidulafungin BID; or vehicle BID. Treatment began 2 h postinoculation and continued for 7 days. Survival was monitored until day 16. Survival was plotted by Kaplan-Meier analysis, and differences in the percent survival among groups were analyzed by the log-rank test and the Fisher exact test, respectively. Abbreviations: APX, APX001A; AFG, anidulafungin. *, P ≤ 0.0001 versus vehicle control; †, P ≤ 0.05 versus anidulafungin.
FIG 1 Survival curves in mice infected with C. auris CBS 12766. Treatments were administered by i.p. injection (n = 10/group): APX001 at doses of 78 mg/kg BID, 78 mg/kg TID, or 104 mg/kg BID; 10 mg/kg anidulafungin BID; or vehicle BID. Treatment began 2 h postinoculation and continued for 7 days. Survival was monitored until day 16. Survival was plotted by Kaplan-Meier analysis, and differences in the percent survival among groups were analyzed by the log-rank test and the Fisher exact test, respectively. Abbreviations: APX, APX001A; AFG, anidulafungin. *, P ≤ 0.0001 versus vehicle control; †, P ≤ 0.05 versus anidulafungin.CC BY · PubMed Central
FIG 2 Reduction in fungal burden in the mouse kidneys, lungs, and brains at 48 h postinfection with C. auris CBS 12766. Treatments were administered by i.p. injection (n = 5/group): APX001 at doses of 78 mg/kg BID or 78 mg/kg TID; 10 mg/kg anidulafungin BID; or vehicle control BID. Treatment began at 2 h postinoculation and continued for 2 days. Animals were sacrificed at 48 h, and the fungal burden was determined. Differences in mean CFU in mouse kidneys, lungs, and brains were compared to the vehicle control using a one-way ANOVA with a post hoc Tukey test. Abbreviations: APX, APX001; AFG, anidulafungin. *, P ≤ 0.001 versus control.
FIG 2 Reduction in fungal burden in the mouse kidneys, lungs, and brains at 48 h postinfection with C. auris CBS 12766. Treatments were administered by i.p. injection (n = 5/group): APX001 at doses of 78 mg/kg BID or 78 mg/kg TID; 10 mg/kg anidulafungin BID; or vehicle control BID. Treatment began at 2 h postinoculation and continued for 2 days. Animals were sacrificed at 48 h, and the fungal burden was determined. Differences in mean CFU in mouse kidneys, lungs, and brains were compared to the vehicle control using a one-way ANOVA with a post hoc Tukey test. Abbreviations: APX, APX001; AFG, anidulafungin. *, P ≤ 0.001 versus control.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 28 · Cited by 139

Research works printed but not linked: 4

  1. Hata K, Horii T, Miyazaki M, Watanabe NA. 2011. In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210. Intersci Conf Antimicrob Agents Chemother, abstr F1-1377.
  2. Watanabe NA, Horii T, Miyazaki M, Hata K. 2011. In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals. Intersci Conf Antimicrob Agents Chemother, abstr F1-1378.
  3. CLSI. 2016. Epidemiological cutoff values for antifungal susceptibility testing, 1st ed, supplement M59. Clinical and Laboratory Standards Institute, Wayne, PA.
  4. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. Document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.

Metadata

Authors
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A.
Affiliations
  • University Hospitals Cleveland Medical Center (US)
  • Center for Medical Mycology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, USA
  • Amplyx Pharmaceuticals (United States) (US)
Corresponding author
Ghannoum, Mahmoud A.
Venue
Antimicrobial Agents and Chemotherapy
Published
2018-03
Volume
62
Issue
3
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2783397783
Cited by
139
References
28
Citations by year
2026: 7 · 2025: 7 · 2024: 6 · 2023: 18 · 2022: 19 · 2021: 24 · 2020: 22 · 2019: 20 · 2018: 16
FWCI
15.49
Type
journal article
Language
en
Open access
Licence
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords
Candida auris, antifungal agents, multidrug resistance, antifungal susceptibility, prodrugs, systemic candidiasis, anidulafungin, emerging fungal pathogens
MeSH terms
Anidulafungin, Aminopyridines, Amphotericin B, Animals, Antifungal Agents, Brain, Candida, Candidiasis, Dose-Response Relationship, Drug, Female, Isoxazoles, Kidney, Lung, Microbial Sensitivity Tests, Prodrugs, Fluconazole, Survival Analysis, Immunocompromised Host, Mice, Echinocandins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris. https://app.cochat.ai/papers/10.1128/aac.02319-17
The paper
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018). In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02319-17

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.